Modeling Hematological Diseases And Cancer With Patient-Specific Induced Pluripotent Stem Cells
- 1Icahn School of Medicine at Mount Sinai, United States
The advent of induced pluripotent stem cells (iPSCs) together with recent advances in genome editing, microphysiological systems, tissue engineering and xenograft models present new opportunities for the investigation of hematological diseases and cancer in a patient-specific context. Here we review the progress in the field and discuss the advantages, limitations and challenges of iPSC-based malignancy modeling. We will also discuss the use of iPSCs and its derivatives as cellular sources for drug target identification, drug development and evaluation of pharmacological responses.
Keywords: Cancer, Blood disorders, Hematopoietic malignancies, Induced Pluripotent Stem Cells, model systems
Received: 29 Jun 2018;
Accepted: 10 Sep 2018.
Edited by:Rhodri Ceredig, National University of Ireland Galway, Ireland
Reviewed by:Encarnacion Montecino-Rodriguez, University of California, Los Angeles, United States
Kay L. Medina, Mayo Clinic, United States
Geoffrey Brown, University of Birmingham, United Kingdom
Copyright: © 2018 Kim and Schaniel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Christoph Schaniel, Icahn School of Medicine at Mount Sinai, New York City, United States, firstname.lastname@example.org